ArticleJACC. Asia2026
Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment: Postmarketing Surveillance Study in Japan.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Status of the Safety and Efficacy of Antidotes for Direct Oral Anticoagulants in Japan.JACC. Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndexanet alfa, a reversal agent for factor Xa inhibitors (FXaI), has demonstrated efficacy and safety for treatment of FXaI-associated major bleeding in clinical trials in a largely Western population with a limited Japanese sample size.
objectivesThis postmarketing surveillance study evaluated andexanet alfa, particularly the safety profile, in Japanese patients with life-threatening or uncontrolled bleeding following FXaI therapy under real-world clinical conditions.
methodsEnrolled patients prescribed andexanet alfa for treatment of life-threatening or uncontrolled bleeding during treatment with an FXaI were followed for up to 30 days after andexanet alfa administration. Key outcomes of interest were safety (including adverse drug reactions, rebleeding events, and thrombotic events) and effectiveness (including physician-reported treatment effectiveness).
resultsOf 1,283 patients enrolled at 388 study sites, 365 patients (63.3% men [231 of 365]; median age 80.0 years [min-max 39-97 years]) were included in safety analyses. The median duration of the follow-up period was 34.0 days (min-max 1-396 days). A total of 86 adverse drug reactions were reported in 64 patients (17.5%), with 2 (0.5%) of 365 patients experiencing infusion reactions. Five (1.4%) of 365 patients met the physician assessment criteria for rebleeding. A total of 32 (8.8%) of 365 patients experienced 34 thrombotic events, most commonly cerebral infarction (6.6% [24 of 365]). Kaplan-Meier analysis yielded a 30-day survival rate of 83.5% (95% CI: 77.4%-88.0%) overall, and physician's assessment of andexanet alfa treatment was "effective" or "excellent" for 80.9% (157 of 194) of patients.
conclusionsThis study supports the safety and effectiveness of andexanet alfa in a real-world population of Japanese patients with FXaI-associated major bleeds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.